利培酮对精神分裂症患者血浆IL-2 IL-6 IL-8的影响及临床意义

目的探讨利培酮治疗前后首发精神分裂症患者血浆白介素-2、白介素-6、白介素-8的变化及临床意义。方法45例首发精神分裂症患者用固定剂量的利培酮进行10周治疗,采用酶联免疫吸附法（ELISA）对治疗前后血浆白介素-2、白介素-6、白介素-8进行了检测。以40例健康志愿者为对照。结果治疗前精神分裂症患者血浆IL-2、IL-6、IL-8水平均显著高于对照组（P〈0.05,P〈0.01）;治疗后患者组血浆IL-2、IL-6水平有显著下降（P〈0.01）,而IL-8水平变化不明显（P〉0.05）。结论精神分裂症患者存在IL-2、IL-6、IL-8介导的免疫功能紊乱,利培酮可能通过抑制IL-2、IL-6的生成而对精神分裂症的免疫功能紊乱进行纠正。

The change of plasma IL-2,IL-6,IL-8 after risperidone treatment in first-episode schizophrenics and their clinical significance

Objective To explore the change of plasma Interleulkin-2（IL-2） ,Interleulkin-6（IL-6） ,Interleulkin- 8（IL-8） levels after risperidone treatment in first-episode schizophrenics and their clinical significance. Methods The plasma levels of IL-2,IL-6 and IL-8 were measured with enzyme-linked immunosorbent assay（ELISA） in 40 healthy volunteers（control group） and 45 first-episode schizophrenic patients（study group）. Results Comparing with control group, the plasma levels of IL-2,IL-6,IL-8 in study group before treatment increased significantly （P〈0. 05;P〈0. 01）. After treatment, the levels of IL-2 and IL-6 in study group decreased significantly （P〈0.01）,but the levels of IL-8 had no significant change（P〉0.05）. Conclusion The patients with schizophrenia have immune dysfunction mediated by IL-2,IL-6 and IL-8. Risperidone may have in-hibitory regulation effect on the immune dysfunction.